Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Penetrance of different cancer types in families with Li-Fraumeni syndrome: a validation study using multi-center cohorts.

Shin SJ, Dodd-Eaton EB, Peng G, Bojadzieva J, Chen J, Amos CI, Frone MN, Khincha P, Mai PL, Savage SA, Ballinger ML, Thomas DM, Yuan Y, Strong LC, Wang W.

Cancer Res. 2019 Nov 12. pii: canres.0728.2019. doi: 10.1158/0008-5472.CAN-19-0728. [Epub ahead of print]

PMID:
31719101
2.

Penetrance estimates over time to first and second primary cancer diagnosis in families with Li-Fraumeni syndrome: a single institution perspective.

Shin SJ, Dodd-Eaton EB, Gao F, Bojadzieva J, Chen J, Kong X, Amos CI, Ning J, Strong LC, Wang W.

Cancer Res. 2019 Nov 12. pii: canres.0725.2019. doi: 10.1158/0008-5472.CAN-19-0725. [Epub ahead of print]

PMID:
31719099
3.

Bayesian Semiparametric Estimation of Cancer-specific Age-at-onset Penetrance with Application to Li-Fraumeni Syndrome.

Shin SJ, Yuan Y, Strong LC, Bojadzieva J, Wang W.

J Am Stat Assoc. 2019;114(526):541-552. doi: 10.1080/01621459.2018.1482749. Epub 2018 Aug 15.

4.

Bayesian estimation of a semiparametric recurrent event model with applications to the penetrance estimation of multiple primary cancers in Li-Fraumeni syndrome.

Shin SJ, Li J, Ning J, Bojadzieva J, Strong LC, Wang W.

Biostatistics. 2018 Nov 14. doi: 10.1093/biostatistics/kxy066. [Epub ahead of print]

PMID:
30445420
5.

Whole body magnetic resonance imaging (WB-MRI) and brain MRI baseline surveillance in TP53 germline mutation carriers: experience from the Li-Fraumeni Syndrome Education and Early Detection (LEAD) clinic.

Bojadzieva J, Amini B, Day SF, Jackson TL, Thomas PS, Willis BJ, Throckmorton WR, Daw NC, Bevers TB, Strong LC.

Fam Cancer. 2018 Apr;17(2):287-294. doi: 10.1007/s10689-017-0034-6.

PMID:
28988289
6.

Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis.

Ballinger ML, Best A, Mai PL, Khincha PP, Loud JT, Peters JA, Achatz MI, Chojniak R, Balieiro da Costa A, Santiago KM, Garber J, O'Neill AF, Eeles RA, Evans DG, Bleiker E, Sonke GS, Ruijs M, Loo C, Schiffman J, Naumer A, Kohlmann W, Strong LC, Bojadzieva J, Malkin D, Rednam SP, Stoffel EM, Koeppe E, Weitzel JN, Slavin TP, Nehoray B, Robson M, Walsh M, Manelli L, Villani A, Thomas DM, Savage SA.

JAMA Oncol. 2017 Dec 1;3(12):1634-1639. doi: 10.1001/jamaoncol.2017.1968. Erratum in: JAMA Oncol. 2018 Apr 1;4(4):590.

7.

The psychosocial effects of the Li-Fraumeni Education and Early Detection (LEAD) program on individuals with Li-Fraumeni syndrome.

Ross J, Bojadzieva J, Peterson S, Noblin SJ, Yzquierdo R, Askins M, Strong L.

Genet Med. 2017 Sep;19(9):1064-1070. doi: 10.1038/gim.2017.8. Epub 2017 Mar 16.

8.

Estimating TP53 Mutation Carrier Probability in Families with Li-Fraumeni Syndrome Using LFSPRO.

Peng G, Bojadzieva J, Ballinger ML, Li J, Blackford AL, Mai PL, Savage SA, Thomas DM, Strong LC, Wang W.

Cancer Epidemiol Biomarkers Prev. 2017 Jun;26(6):837-844. doi: 10.1158/1055-9965.EPI-16-0695. Epub 2017 Jan 30.

9.

Early onset HER2-positive breast cancer is associated with germline TP53 mutations.

Melhem-Bertrandt A, Bojadzieva J, Ready KJ, Obeid E, Liu DD, Gutierrez-Barrera AM, Litton JK, Olopade OI, Hortobagyi GN, Strong LC, Arun BK.

Cancer. 2012 Feb 15;118(4):908-13. doi: 10.1002/cncr.26377. Epub 2011 Jul 14. Erratum in: Cancer. 2012 May 1;118(9):2561.

Supplemental Content

Loading ...
Support Center